B05
Targeting OTUD6B in multiple myeloma
Project Summary
In this project, Florian Bassermann and Kamyar Hadian will build on previous work of the Bassermann group that characterized the DUB OTUD6B as a central vulnerability in multiple myeloma. OTUD6B determines the proliferative state of this disease by targeting and stabilizing the RNA binding protein LIN28B at the G1/S transition, leading to high MYC abundance and activity. Using high throughput screening and other screening technologies, we will identify and validate OTUD6B inhibitory compounds. We will also synthesize compound analogs to generate molecules with enhanced potency. The team expects to generate the first in vitro and in vivo validated OTUD6B inhibitors that inhibit multiple myeloma progression. These molecules will be then be optimized for preclinical development.
